The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
Roberts
H R
HR
Center for Thrombosis and Hemostasis University of North Carolina at Chapel Hill, Chapel Hill, N.C., USA.
D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors / Q000276:immunology / Q000627:therapeutic use*; D005169:Factor VIII / Q000276:immunology* / Q000627:therapeutic use; D015942:Factor VIIa / Q000627:therapeutic use; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use
D001779:Blood Coagulation Factors; D007518:Isoantibodies; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; D005169:Factor VIII; D015942:Factor VIIa